A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.

Trial Profile

A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs Carbidopa/XP-21279 (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 05 Dec 2011 Primary endpoint 'Off-time' has not been met, according to a XenoPort media release.
    • 04 Aug 2011 Top-line results are expected by the end of 2011, according to a XenoPort media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top